Halle (Saale), 2. August 2023. Icon Genetics GmbH, a wholly owned subsidiary of Denka Co. Ltd, Tokyo, Japan, announced today that it has been granted a European patent (EP3938378B1) for its invention on norovirus-like particles with improved stability. The patent application was filed on 11. March 2020 and granted on 2. August 2023. The invention… Read more »
Month: February 2024
Icon Genetics has published a second milestone paper further detailing the remarkable immune responses elicited by the novel norovirus vaccine candidate in a successfully completed phase i clinical study
Halle (Saale), 26 June 2023. Icon Genetics GmbH, a wholly owned subsidiary of Denka Co. Ltd, Tokyo, Japan, has published a second milestone paper in the renowned journal “Frontiers in Immunology” detailing on the remarkable immune responses elicited by its norovirus vaccine candidate during the successfully completed Phase I clinical study. Noroviruses are responsible… Read more »
Icon Genetics has published a first milestone paper about the successfully completed phase i clinical study of a novel norovirus vaccine
Halle (Saale), 07. October 2022. Icon Genetics GmbH, a wholly owned subsidiary of Denka Co. Ltd, Tokyo, Japan, has successfully completed a Phase I clinical study of its norovirus vaccine candidate and published a first milestone paper in the renowned journal “Frontiers in Immunology”. Noroviruses are responsible for approximately 20% of all cases of acute… Read more »
Icon Genetics has published a milestone paper about the successfully completed pre-clinical evaluation of a novel norovirus vaccine candidate
Halle (Saale), 11. February 2022. Icon Genetics GmbH, a wholly owned subsidiary of Denka Co. Ltd, Tokyo, Japan, has successfully completed pre-clinical evaluation of its norovirus vaccine candidate supporting clinical testing in humans and published a milestone paper in the renowned journal “Vaccine”. Noroviruses are responsible for approximately 20% of all cases of acute… Read more »
Recent Comments